Bleeding risk in patients with atrial fibrillation on anticoagulation

What it is and when to use it

The HAS-BLED score estimates the risk of major bleeding in patients with atrial fibrillation who are candidates for, or already receiving, oral anticoagulation. It assigns one point for each of the following: uncontrolled hypertension (HAS, systolic blood pressure above 160 mmHg), abnormal renal or liver function (Abnormal, one point each), prior stroke (Stroke), bleeding history or predisposition (Bleeding), labile INR (Labile, applicable only to patients on vitamin K antagonists), elderly age over 65 years (Elderly), and concomitant antiplatelet or NSAID drugs or alcohol use (Drugs/alcohol, one point each). The ESC 2024 guidelines on atrial fibrillation recommend assessing and correcting modifiable bleeding risk factors but advise against using the score in isolation to withhold anticoagulation.

How to interpret it

The score ranges from 0 to 9 points. A value of 0 to 2 is considered low-to-moderate bleeding risk, whereas a score of 3 or higher indicates high risk and identifies patients who warrant caution, closer clinical follow-up, and active correction of modifiable factors. A high HAS-BLED score is not in itself a contraindication to anticoagulation: it flags the need for vigilance, not treatment withdrawal.

Limitations and when not to use it

The score was validated in patients with atrial fibrillation, and the labile INR component applies only to those on vitamin K antagonists, not to direct oral anticoagulants. Its purpose is to identify and correct modifiable risk factors, not to exclude anticoagulation in patients who have an indication for it. The most frequent misuse is applying it to deny treatment; it should always be interpreted alongside embolic risk (CHA₂DS₂-VASc), as it does not assess stroke risk or the net clinical benefit of anticoagulation.

Frequently asked questions

What does a HAS-BLED score of 3 or more mean?

It indicates high bleeding risk. It does not contraindicate anticoagulation, but it calls for correcting modifiable factors and closer clinical follow-up.

Should HAS-BLED be used to decide not to anticoagulate?

No. A high score is not a reason to withhold anticoagulation; it is used to identify and correct bleeding risk factors and to intensify monitoring.

What is the difference between HAS-BLED and CHA₂DS₂-VASc?

CHA₂DS₂-VASc estimates stroke risk and guides whether to anticoagulate; HAS-BLED estimates bleeding risk. They are used together, not as mutually exclusive tools.